Global Non-Invasive Prenatal Testing (NIPT) Market-Trends, Analysis, and Forecast till 2029

 

Introduction

A Non-Invasive Prenatal Testing (NIPT) is a screening test to identify if the unborn child/fetus is at risk for a number of genetic disorders like Down syndrome, Edwards syndrome, Patau syndrome, etc. The test is done by using blood sample thus reducing the risk of miscarriage during testing to absolute nil coupled with the ability to screen for a number of disorders within 10 weeks in pregnancy, much earlier as compared to any other prenatal diagnostic tests. NIPT has been ranked as the most successful, sensitive and the most accurate test thereby being the mostly preferred test. The global non-invasive prenatal testing (NIPT) market accounted for US$ XX billion in 2019 and is estimated to be US$ XX billion by 2029 and is anticipated to register a CAGR of XX%........ Read More

Get Sample Copy of This Report - https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4519

COVID-19 Impact on the Market:

The COVID-19 pandemic has affected various businesses. The major concern being the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. However, government across the countries has imposed strict lockdown to limit the spread of disease.  This has hindered the industrial supply chain and also disrupted the production segment. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. This report will quantify the impact of this pandemic on the non-invasive prenatal testing (NIPT) market.

Request Discount- 

https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/4519 

Key Players:

The key players operating in the non-invasive prenatal testing (NIPT) market include Sequenom, Roche (Ariosa Diagnostics); Natera, LabCorp, BGI Genomics; Quest Diagnostics, Illumina, Laboratory Corporation of America Holdings, Yourgene Health, and Berry Genomics. For instance, in June 2019, BGI and Eluthia (Germany) launched the NIFTY test (non-invasive prenatal test), under the brand name PreviaTest in Germany. Further, in January 2019, Yourgene Health plc (U.K.) launched the Sage 32 plex test which uses Thermo Fisher’s Ion Torrent sequencing technology to detect placental cff-DNA in a maternal blood sample.

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

CONTACT US:

Sales 

Prophecy Market Insights

Phone: +1 860 531 2701

Email: sales@prophecymarketinsights.com

Connect With Us:-